Cencora, Inc. (COR) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Cencora, Inc. (COR) Healthcare & Pipeline Overview

Cencora, Inc., a global healthcare solutions company, specializes in pharmaceutical sourcing and distribution. Operating through U.S. and international segments, Cencora serves diverse healthcare providers and manufacturers with pharmaceuticals, services, and commercialization solutions. With a $61.6B market cap, Cencora navigates the competitive pharmaceutical distribution landscape.

What Is the Investment Thesis for COR?

Cencora, Inc. presents a stable investment opportunity within the healthcare distribution sector. With a market capitalization of $61.6B and a P/E ratio of 21.6, the company demonstrates financial stability. A key value driver is its established distribution network and comprehensive service offerings, which cater to a diverse customer base. Growth catalysts include the increasing demand for specialty pharmaceuticals and the expansion of its international operations. However, investors may want to evaluate potential risks such as pricing pressures and regulatory changes in the pharmaceutical industry. The company's beta of 0.72 indicates lower volatility compared to the market, making it a potentially noteworthy option for risk-averse investors. The dividend yield of 0.88% provides a modest income stream.

Based on FMP financials and quantitative analysis

COR Key Highlights

Market Cap of $61.6B reflects Cencora's significant presence in the pharmaceutical distribution market.

• P/E Ratio of 21.6 indicates the valuation of the company relative to its earnings.
• Gross Margin of 3.5% demonstrates the company's profitability after accounting for the cost of goods sold.
• Dividend Yield of 0.88% provides a steady income stream for investors.
• Beta of 0.72 suggests lower volatility compared to the overall market, indicating a relatively stable investment.

Who Are COR's Competitors?

COR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are COR's Key Strengths?

Extensive distribution network in the U.S. and internationally.

• Diverse product portfolio including pharmaceuticals, healthcare products, and animal health products.
• Strong relationships with pharmaceutical manufacturers and healthcare providers.
• Comprehensive service offerings including pharmacy management, consulting, and data analytics.

What Are COR's Weaknesses?

Low profit margin compared to other healthcare companies.

• Exposure to pricing pressures and regulatory changes in the pharmaceutical industry.
• Dependence on a few large customers.
• Limited brand recognition compared to consumer-facing healthcare companies.

What Could Drive COR Stock Higher?

Expansion of specialty pharmaceutical services driving revenue growth.

• International market expansion increasing global market share.
• Potential acquisitions of companies with complementary capabilities by Q4 2026.
• Development of innovative supply chain solutions improving efficiency.

What Are the Key Risks for COR?

Increasing competition from other pharmaceutical distributors impacting market share.

• Pricing pressures from generic drugs and managed care organizations reducing profit margins.
• Regulatory changes such as drug pricing controls affecting revenue.
• Supply chain disruptions due to geopolitical events or natural disasters impacting distribution.
• Dependence on key customers exposes Cencora to financial risk if those relationships are disrupted.

What Are the Growth Opportunities for COR?

• Expansion of Specialty Pharmaceutical Services: Cencora can capitalize on the growing demand for specialty pharmaceuticals, which require specialized handling and distribution. The specialty pharmaceutical market is projected to reach $840 billion globally by 2026. By expanding its capabilities in this area, Cencora can increase its revenue and profitability. This includes offering services such as cold chain logistics, patient support programs, and data analytics for pharmaceutical manufacturers.
• International Market Expansion: Cencora has the opportunity to expand its presence in international markets, particularly in emerging economies with growing healthcare needs. The global pharmaceutical market is expected to reach $1.5 trillion by 2026, with significant growth coming from developing countries. By establishing partnerships and acquisitions in these markets, Cencora can diversify its revenue streams and reduce its reliance on the U.S. market.
• Enhancement of Data Analytics and Consulting Services: Cencora can leverage its data analytics capabilities to provide valuable insights and consulting services to pharmaceutical manufacturers and healthcare providers. The market for healthcare analytics is projected to reach $34 billion by 2026. By offering services such as market research, sales force effectiveness analysis, and patient outcome studies, Cencora can strengthen its relationships with its customers and generate additional revenue.
• Strategic Acquisitions and Partnerships: Cencora can pursue strategic acquisitions and partnerships to expand its service offerings and geographic reach. The healthcare distribution industry is consolidating, with larger players acquiring smaller companies to gain market share. By acquiring companies with complementary capabilities, Cencora can enhance its competitive position and drive growth. Potential targets include companies specializing in specialty pharmacy, healthcare logistics, and data analytics.
• Development of Innovative Supply Chain Solutions: Cencora can invest in developing innovative supply chain solutions to improve efficiency and reduce costs. This includes implementing technologies such as blockchain, artificial intelligence, and the Internet of Things to optimize inventory management, track shipments, and prevent counterfeiting. By improving its supply chain efficiency, Cencora can enhance its profitability and provide better service to its customers.

What Are COR's Competitive Advantages?

• Established distribution network with extensive reach.
• Strong relationships with pharmaceutical manufacturers and healthcare providers.
• Comprehensive service offerings including distribution, consulting, and data analytics.
• Scale and efficiency in pharmaceutical distribution.

What Does COR Do?

Founded in 1871 and headquartered in Conshohocken, Pennsylvania, Cencora, Inc., formerly known as AmerisourceBergen Corporation, is a global leader in pharmaceutical sourcing and distribution. The company operates through two primary segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a wide array of products, including generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies, and equipment. It serves acute care hospitals, retail pharmacies, mail order pharmacies, medical clinics, and long-term care facilities. This segment also distributes specialty pharmaceutical products like plasma and vaccines, and provides pharmacy management, staffing, and consulting services. Additionally, it offers supply management software, packaging solutions, clinical trial support, and data analytics services. The International Healthcare Solutions segment focuses on pharmaceutical wholesale and related services, distributing pharmaceuticals and healthcare products to pharmacies, doctors, health centers, and hospitals internationally. It also provides specialty transportation and logistics services for the biopharmaceutical industry. Cencora's evolution reflects its commitment to adapting to the changing healthcare landscape, expanding its services to meet the needs of both healthcare providers and pharmaceutical manufacturers. The company changed its name to Cencora, Inc. in August 2023, marking a new chapter in its long history.

What Products and Services Does COR Offer?

• Distributes generic and injectable pharmaceuticals.
• Provides over-the-counter healthcare products.
• Offers home healthcare supplies and equipment.
• Distributes plasma and other blood products.
• Provides pharmacy management and staffing services.
• Offers supply management software to healthcare providers.
• Provides clinical trial support and commercialization services.
• Distributes pharmaceuticals and vaccines for the animal health market.

How Does COR Make Money?

• Generates revenue by distributing pharmaceutical products to healthcare providers.
• Provides value-added services such as pharmacy management and consulting.
• Offers data analytics and market research services to pharmaceutical manufacturers.
• Operates through U.S. and International Healthcare Solutions segments.

What Industry Does COR Operate In?

Cencora, Inc. operates in the medical distribution industry, which is characterized by increasing demand for pharmaceuticals and healthcare products. The industry is influenced by factors such as an aging population, rising healthcare expenditures, and advancements in medical technology. Cencora competes with other major distributors, such as Becton, Dickinson and Company (BDX), and faces challenges related to pricing pressures, regulatory compliance, and supply chain management. The market is also seeing a trend towards consolidation, with larger players acquiring smaller distributors to expand their geographic reach and service offerings. Cencora's established distribution network and comprehensive service portfolio position it well to capitalize on the industry's growth opportunities.

Who Are COR's Key Customers?

• Acute care hospitals and health systems.
• Independent and chain retail pharmacies.
• Mail order pharmacies.
• Medical clinics.
• Long-term care and alternate site pharmacies.

Company Profile

Cencora, Inc. operates in the Medical - Distribution industry within the Healthcare sector. It is headquartered in Conshohocken, US. The company is led by CEO Robert Mauch. COR has traded publicly since 1995.

Cencora, Inc. Financial Trajectory

Cencora, Inc. (COR) reported $84.75B in revenue for Q2 2026, reflecting 8.2% growth compared to the prior quarter. The company recorded net income of $763.5M, with diluted EPS of $3.94. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, COR averaged $3.37 in diluted EPS.

How Cencora, Inc. Is Valued

Cencora, Inc. carries a market capitalization of $61.6B, placing it in the large-cap category. Relative to its peer group, COR's quantitative score of 80/100 is roughly in line with the peer average of 74/100.

Return on equity for Cencora, Inc. stands at 115.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.1%, showing how much profit it generates from its asset base. COR trades at a trailing price-to-earnings ratio of 21.60, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 2.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.95 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 4.6%, the inverse of the P/E and a quick read on earnings relative to price.

Cencora, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 4.69 places it in the safe zone, indicating low near-term bankruptcy risk.

Cencora, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 3.1% above estimates on average.

Wall Street analysts project Cencora, Inc. revenue of about $337.53B for fiscal 2026, with EPS near $17.82. The estimate reflects 9 contributing analysts.

Over the past six months, Cencora, Inc. insiders filed 13 SEC Form 4 transactions — 2 sales and 11 purchases. On net that is roughly 31K shares acquired (about $1.1M) — insiders putting money in tends to read as conviction.

COR Financials

COR earnings history & estimates →

COR Latest News

COR Analyst Consensus

COR MoonshotScore

Latest Cencora, Inc. Analysis

Common Questions About COR (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources